← Back to Search

CAR T-cell Therapy

Active Intervention with CAR T for Dermatomyositis

Phase 1

Waitlist Available

Led By David Fiorentino, MD, PhD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 weeks

Awards & highlights

Study Summary

"This trial aims to study the effects of CAR T therapy in adult patients with dermatomyositis, an autoimmune disease. The therapy involves modifying white blood cells to target and kill specific cells in the immune

Who is the study for?

This trial is for adults with dermatomyositis, an autoimmune disease. Participants must have their own T cells modified to target B cells that may be causing the disease. It's not specified who can't join, but typically those with other serious health issues or immune deficiencies might be excluded.Check my eligibility

What is being tested?

The study tests KYV-101 Anti-CD19 CAR T Therapy in adults with dermatomyositis. Patients' T cells are engineered to destroy B cells by recognizing CD19 protein, potentially resetting the immune system and alleviating the disease.See study design

What are the potential side effects?

Potential side effects include reactions related to immune system changes such as flu-like symptoms, fatigue, fever, and possibly more severe complications due to a significant alteration of the immune response.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants experiencing adverse events

Trial Design

1Treatment groups

Experimental Treatment

Group I: Active Intervention with CAR TExperimental Treatment1 Intervention

All participants in the trial will receive an infusion of autologous, genetically modified CAR T cells specific for the CD19 antigen

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,394 Previous Clinical Trials

17,341,589 Total Patients Enrolled

1 Trials studying Dermatomyositis

5 Patients Enrolled for Dermatomyositis

David Fiorentino, MD, PhDPrincipal InvestigatorStanford University

Everett Meyer, MDPrincipal InvestigatorStanford University

2 Previous Clinical Trials

26 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which individuals are considered ideal candidates to participate in this research study?

"Individuals aged between 25 and 72 years diagnosed with dermatomyositis are eligible to enroll in this study, which aims to recruit a total of 21 participants."

Answered by AI

Is the research study open to individuals who have surpassed their fiftieth year of life?

"In compliance with the trial's eligibility requirements, individuals must be at least 25 years old but no more than 72 years old to qualify for participation."

Answered by AI

What are the safety considerations for using CAR T in active treatment interventions for individuals?

"Given that this is a Phase 1 study with limited safety and efficacy data, our team at Power assigns an estimated safety rating of 1 to the Active Intervention involving CAR T therapy."

Answered by AI

Are potential participants still able to apply for enrollment in this ongoing research study?

"As per clinicaltrials.gov, the current trial is not in an active recruitment phase. The trial was initially listed on April 1st, 2024 and last updated on February 29th, 2024. Although this specific study is not enrolling participants currently, there are a total of 28 other trials actively seeking candidates at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

David Fiorentino 2024. "Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06298019.

All > Myositis > Dermatomyositis